Merck & Co., Inc. (NYSE:MRK) Releases Earnings Results, Beats Expectations By $0.13 EPS

Key Points

• Merck beat quarterly expectations: Revenue rose 5.1% year over year to $16.61 billion, topping estimates, while its $0.13-per-share loss was narrower than the expected $0.26 loss.
• Revenue outlook improved, but profit guidance fell: Merck raised its 2026 revenue forecast to $66.3 billion–$67.3 billion while cutting adjusted EPS guidance to $2.66–$2.76, largely due to acquisition-related charges from Terns Pharmaceuticals.
• Growth beyond Keytruda is gaining momentum: WINREVAIR, WELIREG and CAPVAXIVE posted strong sales growth, while positive clinical results and regulatory progress expanded the company’s longer-term pipeline prospects.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) issued its earnings results on Tuesday. The company reported ($0.13) EPS for the quarter, topping the consensus estimate of ($0.26) by $0.13, FiscalAI reports. Merck & Co., Inc. had a return on equity of 27.55% and a net margin of 13.59%.The business had revenue of $16.61 billion during the quarter, compared to analysts' expectations of $16.37 billion. During the same quarter last year, the firm posted $2.13 earnings per share. Merck & Co., Inc.'s revenue was up 5.1% compared to the same quarter last year. Merck & Co., Inc. updated its FY 2026 guidance to 2.660-2.760 EPS.

Here are the key takeaways from Merck & Co., Inc.'s conference call:

• Merck raised and narrowed its 2026 revenue outlook to $66.3 billion–$67.3 billion, while maintaining confidence in continued growth driven by oncology, animal health, and newer product launches.
• New and expanding products showed strong momentum, including WINREVAIR sales up 75%, WELIREG sales up 67%, and CAPVAXIVE sales up 40%; LIPFENDRA also received FDA approval as the first oral PCSK9 inhibitor.
• Pipeline de-risking accelerated, with positive Phase III results for sac-TMT in endometrial cancer and tulisokibart in ulcerative colitis, while weekly oral HIV-treatment data and multiple upcoming regulatory milestones support Merck’s projected long-term growth opportunities.
• Second-quarter reported EPS was a loss of $0.13, including a $2.31-per-share one-time charge tied to the Terns acquisition; Merck also expects U.S. KEYTRUDA growth to moderate, an OHTUVAYRE sales unwind in the third quarter, and higher inventory reserves to pressure margins.

Merck & Co., Inc. Stock Up 0.4%

MRK traded up $0.54 during trading on Tuesday, reaching $128.31. 3,403,931 shares of the stock traded hands, compared to its average volume of 10,762,633. The stock has a market cap of $316.91 billion, a price-to-earnings ratio of 36.14, a price-to-earnings-growth ratio of 5.17 and a beta of 0.19. Merck & Co., Inc. has a fifty-two week low of $77.58 and a fifty-two week high of $135.05. The company has a debt-to-equity ratio of 1.02, a current ratio of 1.30 and a quick ratio of 1.06. The stock's 50-day simple moving average is $123.28 and its two-hundred day simple moving average is $118.66.

Merck & Co., Inc. Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 7th. Investors of record on Tuesday, September 15th will be given a dividend of $0.85 per share. The ex-dividend date of this dividend is Tuesday, September 15th. This represents a $3.40 dividend on an annualized basis and a yield of 2.6%. Merck & Co., Inc.'s dividend payout ratio (DPR) is presently 95.77%.

Key Merck & Co., Inc. News

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck reported second-quarter revenue of $16.61 billion, above the $16.37 billion consensus estimate and up 5.1% year over year. The company also posted a narrower-than-expected loss of $0.13 per share, compared with the expected $0.26 loss. Merck posts better-than-expected second-quarter results on Keytruda strength
• Positive Sentiment: Keytruda remained the primary growth driver, while the newer injectable formulation reportedly generated more than $200 million above Wall Street’s forecast. Strength in oncology and other newer products helped Merck raise its full-year revenue guidance to $66.3 billion-$67.3 billion, broadly consistent with the $66.7 billion consensus. The Merck Product That Absolutely Demolished Wall Street's Forecasts
• Neutral Sentiment: Management highlighted regulatory approvals, clinical progress and a broad development pipeline, which could support longer-term growth as Merck works to diversify beyond Keytruda. Merck announces second-quarter 2026 financial results and pipeline milestones
• Negative Sentiment: Merck cut its fiscal 2026 adjusted EPS guidance to $2.66-$2.76, well below the $3.42 analyst consensus. The reduction reflects acquisition-related charges, particularly costs tied to the purchase of Terns Pharmaceuticals, and overshadows the quarterly earnings beat. Merck hikes revenue outlook but cuts profit guidance due to deal charges
• Negative Sentiment: The quarterly loss compares with earnings of $2.13 per share in the year-ago period, underscoring the near-term impact of acquisition and investment costs on profitability. Merck reports second-quarter loss and beats revenue estimates

Hedge Funds Weigh In On Merck & Co., Inc.

A number of hedge funds have recently added to or reduced their stakes in the company. Sunbeam Capital Management LLC grew its stake in shares of Merck & Co., Inc. by 1.3% in the 4th quarter. Sunbeam Capital Management LLC now owns 7,099 shares of the company's stock worth $747,000 after acquiring an additional 94 shares in the last quarter. Rexford Capital Inc. raised its stake in shares of Merck & Co., Inc. by 1.3% during the 4th quarter. Rexford Capital Inc. now owns 7,799 shares of the company's stock worth $821,000 after purchasing an additional 100 shares during the period. Wealthspire Retirement LLC boosted its holdings in shares of Merck & Co., Inc. by 2.3% in the 4th quarter. Wealthspire Retirement LLC now owns 5,162 shares of the company's stock worth $543,000 after buying an additional 114 shares during the last quarter. Monetary Management Group Inc. increased its holdings in Merck & Co., Inc. by 0.7% during the second quarter. Monetary Management Group Inc. now owns 19,035 shares of the company's stock worth $1,507,000 after buying an additional 125 shares during the last quarter. Finally, Financial Engines Advisors L.L.C. raised its position in Merck & Co., Inc. by 1.3% in the third quarter. Financial Engines Advisors L.L.C. now owns 9,783 shares of the company's stock worth $821,000 after acquiring an additional 125 shares during the period. Institutional investors and hedge funds own 76.07% of the company's stock.

Analyst Upgrades and Downgrades

MRK has been the topic of several recent analyst reports. Cantor Fitzgerald reissued a "neutral" rating and set a $120.00 price target on shares of Merck & Co., Inc. in a research report on Monday, July 6th. Bank of America lifted their target price on Merck & Co., Inc. from $130.00 to $141.00 and gave the company a "buy" rating in a research note on Tuesday, June 30th. BMO Capital Markets upped their target price on Merck & Co., Inc. from $135.00 to $142.00 and gave the company an "outperform" rating in a report on Monday, July 13th. Wall Street Zen lowered shares of Merck & Co., Inc. from a "buy" rating to a "hold" rating in a research report on Monday, July 20th. Finally, Barclays raised their price target on shares of Merck & Co., Inc. from $140.00 to $150.00 and gave the stock an "overweight" rating in a report on Wednesday, July 29th. Thirteen investment analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the company. According to data from MarketBeat, Merck & Co., Inc. has an average rating of "Moderate Buy" and an average target price of $134.50.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.